USP6 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, USP6 is a viable therapeutic target for overcoming resistance in CML treatment because it inhibits GLS1 ubiquitination, which not only improves GLS1 stability but also plays a crucial role in the survival of CML cells under therapeutic stress.